Universal screening at age 1–2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis

Atherosclerosis ◽

10.1016/j.atherosclerosis.2018.05.047 ◽

2018 ◽

Vol 275 ◽

pp. 434-443 ◽

Author(s):

Ailsa J. McKay ◽

Helen Hogan ◽

Steve E. Humphries ◽

Dalya Marks ◽

Kausik K. Ray ◽

...

Keyword(s):

Universal Screening ◽

Familial Hypercholesterolaemia ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Cascade Testing ◽

Download Full-text

Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales

Atherosclerosis ◽

10.1016/j.atherosclerosis.2018.05.021 ◽

2018 ◽

Vol 275 ◽

pp. 80-87 ◽

Author(s):

Paul Crosland ◽

Ross Maconachie ◽

Sara Buckner ◽

Hugh McGuire ◽

Steve E. Humphries ◽

...

Keyword(s):

Electronic Health Records ◽

Familial Hypercholesterolaemia ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Health Records ◽

England And Wales ◽

Cascade Testing ◽

Electronic Health

Download Full-text

Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales

Atherosclerosis ◽

10.1016/j.atherosclerosis.2018.06.184 ◽

2018 ◽

Vol 275 ◽

pp. e67

Author(s):

S. Humphries ◽

P. Crosland ◽

R. Maconachie ◽

S. Buckner ◽

H. Mcguire ◽

...

Keyword(s):

Electronic Health Records ◽

Familial Hypercholesterolaemia ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Health Records ◽

England And Wales ◽

Cascade Testing ◽

Electronic Health

Download Full-text

Model-Based Cost–Utility Analysis of Erythropoiesis-Stimulating Agents for the Treatment of Cancer-Treatment Induced Anaemia in the UK NHS

Value in Health ◽

10.1016/j.jval.2014.08.2316 ◽

2014 ◽

Vol 17 (7) ◽

pp. A641-A642 ◽

Author(s):

T. Snowsill ◽

N. Huxley ◽

M. Hoyle ◽

L. Crathorne ◽

M. Haasova ◽

...

Keyword(s):

Cancer Treatment ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Erythropoiesis Stimulating Agents ◽

Model Based ◽

Download Full-text

Cost utility analysis of cinacalcet in addition to standard of care in the UK

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfm434 ◽

2007 ◽

Vol 22 (11) ◽

pp. 3355-3357 ◽

Author(s):

J. A. Ray ◽

W. J. Valentine ◽

A. J. Palmer

Keyword(s):

Standard Of Care ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Download Full-text

A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK

Journal of Medical Economics ◽

10.1080/13696998.2020.1839273 ◽

2020 ◽

pp. 1-10

Author(s):

V. K. Brennan ◽

F. Colaone ◽

S. Shergill ◽

R. F. Pollock

Keyword(s):

Colorectal Cancer ◽

Supportive Care ◽

Metastatic Colorectal Cancer ◽

Best Supportive Care ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Resin Microspheres ◽

The Uk ◽

Unresectable Metastatic Colorectal Cancer

Download Full-text

A cost-utility analysis of adjunctive treatment with newer antiepileptic drugs in the UK

Journal of Medical Economics ◽

10.3111/200407029040 ◽

2004 ◽

Vol 7 (1-4) ◽

pp. 29-40 ◽

Author(s):

Edit Remák ◽

John Hutton ◽

Caroline E Selai ◽

Michael R Trimble ◽

Martin J Price

Keyword(s):

Antiepileptic Drugs ◽

Cost Utility ◽

Cost Utility Analysis ◽

Adjunctive Treatment ◽

Utility Analysis ◽

Download Full-text

The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK

Journal of the Neurological Sciences ◽

10.1016/s0022-510x(01)00618-9 ◽

2001 ◽

Vol 191 (1-2) ◽

pp. 95-102 ◽

Author(s):

Manouche Tavakoli ◽

M Malek

Keyword(s):

Amyotrophic Lateral Sclerosis ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

The Uk ◽

The Cost ◽

Lateral Sclerosis

Download Full-text

A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK

Journal of Medical Economics ◽

10.1080/13696998.2016.1189921 ◽

2016 ◽

Vol 19 (10) ◽

pp. 995-1002 ◽

Author(s):

Gorden Muduma ◽

Isaac Odeyemi ◽

Richard F. Pollock

Keyword(s):

Liver Transplant ◽

Immediate Release ◽

Cost Utility ◽

Cost Utility Analysis ◽

Prolonged Release ◽

Transplant Recipients ◽

Utility Analysis ◽

The Uk ◽

Liver Transplant Recipients

Download Full-text

PEY16 COST-UTILITY ANALYSIS FOR PEGAPTANIB IN AGE-RELATED MACULAR DEGENERATION IN THE UK: THE IMPACT OF DEMOGRAPHIC AND DISEASE CHARACTERISTICS

Value in Health ◽

10.1016/s1098-3015(10)63722-9 ◽

2006 ◽

Vol 9 (6) ◽

pp. A370 ◽

Author(s):

S Wolowacz ◽

N Roskell ◽

F Maciver ◽

S Kelly

Keyword(s):

Macular Degeneration ◽

Cost Utility ◽

Cost Utility Analysis ◽

Age Related Macular Degeneration ◽

Utility Analysis ◽

Disease Characteristics ◽

Age Related ◽

The Uk ◽

Download Full-text

PGS11 USING A COST-UTILITY ANALYSIS FOR ASSESSING SENSITIVITY IN DRUG PRICES OF ESOMEPRAZOLE VERSUS OMEPRAZOLE IN THE ACUTE TREATMENT OF REFLUX OESOPHAGITIS IN THE UK

Value in Health ◽

10.1016/s1098-3015(10)61757-3 ◽

2003 ◽

Vol 6 (6) ◽

pp. 687

Author(s):

P Wahlqvist

Keyword(s):

Acute Treatment ◽

Reflux Oesophagitis ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Drug Prices ◽

The Uk ◽

Assessing Sensitivity ◽

Reflux Œsophagitis

Download Full-text